1. Indications:

Lornatib (Lorlatinib) 100 mg is indicated for the treatment of:

• Metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive, in patients who have progressed on crizotinib and at least one other ALK inhibitor.
• Metastatic NSCLC with ROS1 rearrangement.

2. Pharmacology:

Lornatib (Lorlatinib) 100 mg exerts its pharmacological effects by selectively inhibiting multiple receptor tyrosine kinases, including ALK, ROS1, and c-MET. By blocking these signaling pathways, Lornatib inhibits cancer cell proliferation, induces apoptosis (programmed cell death), and suppresses tumor growth, ultimately leading to tumor regression and inhibition of cancer progression.

3. Dosage and Administration:

The recommended dosage of Lornatib (Lorlatinib) 100 mg may vary depending on individual patient factors and the specific type of cancer being treated. Generally, the prescribed dose is 100 mg taken orally once daily, with or without food. Treatment should continue until disease progression, unacceptable toxicity, or other treatment discontinuation criteria are met. Dose adjustments or discontinuation may be necessary based on individual patient response and tolerability.

4. Interaction:

Lornatib (Lorlatinib) 100 mg may interact with other medications, including:

• Strong CYP3A inhibitors or inducers: Co-administration with drugs that affect CYP3A metabolism may alter the plasma concentration of Lornatib.
• Acid-reducing agents: Concurrent use of proton pump inhibitors (PPIs) or H2-receptor antagonists may decrease the absorption of Lornatib, potentially reducing its efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Lornatib (Lorlatinib) 100 mg may include:

• Fatigue
• Edema (fluid retention)
• Cognitive effects (memory impairment, confusion)
• Weight gain
• Dyspnea (difficulty breathing)
• Hyperlipidemia (high blood cholesterol levels)

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Lornatib (Lorlatinib) 100 mg, patients should be aware of the following precautions:

• Lornatib may cause cognitive effects, including changes in memory and confusion. Patients should exercise caution when performing activities requiring mental alertness.
• Lornatib may cause hyperlipidemia, which should be monitored and managed appropriately during treatment.
• Lornatib may prolong the QT interval, increasing the risk of arrhythmias. Electrocardiograms (ECGs) should be monitored regularly, especially in patients with pre-existing cardiac conditions.

7. Overdose Effects:

In case of overdose with Lornatib (Lorlatinib) 100 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Lornatib overdose, and patients should seek immediate medical attention if overdose is suspected.